Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
NASDAQ:HOOK
HOOK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.82 - $10.50
Previous CloseN/A
Volume38.61K
Average Volume (3M)62.12K
Market Cap
$10.26M
Enterprise Value-$14.68M
Total Cash (Recent Filing)-$61.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.85
Next Earnings
May 08, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding9,659,522
10 Day Avg. Volume52,031
30 Day Avg. Volume62,116
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.34
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$2.00Price Target Upside143.90% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Hookipa Pharma News
PremiumCompany Announcements
Hookipa Pharma Seeks Validation for Stockholder Meetings
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing Phase 1/2 has completed enrollment well in advance of plan, and updated results continued to highlight the potential superior results for eseba-vec + Keytruda vs. Keytruda monotherapy.
Milestone PaymentsHOOKIPA can earn up to $140M in development milestones for the HBV program, and up to $172.5M for HIV.
Pipeline AdvancementThe combination of eseba-vec and Keytruda continues to show beneficial responses in first-line head-and-neck cancer, supporting a Market Outperform rating for Hookipa Pharma.
Bears Say
Dilution RiskCurrent Hookipa shareholders are expected to face significant dilution.
Merger UncertaintyAll discussions regarding the merger with Poolbeg have been non-binding and non-exclusive, increasing uncertainty about Hookipa’s future path.
Pipeline UncertaintyUncertainty regarding Hookipa’s pipeline development and a near-term dilution risk has led to a downgrade of HOOK to Neutral from Buy.
---
Ownership Overview
3.49% Insiders
5.29% Mutual Funds
39.50% Other Institutional Investors
49.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $0.81 and its highest was $10.50 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Hookipa Pharma Inc’s market cap is $10.26M.
When is Hookipa Pharma Inc’s upcoming earnings report date?
Hookipa Pharma Inc’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were Hookipa Pharma Inc’s earnings last quarter?
Hookipa Pharma Inc released its earnings results on Mar 20, 2025. The company reported -$1.95 earnings per share for the quarter, missing the consensus estimate of -$1.123 by -$0.827.
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate is -0.83.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 9,659,522 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Hookipa Pharma Inc reported an EPS of -$1.95 in its last earnings report, missing expectations of -$1.123. Following the earnings report the stock price went up 0.82%.
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Currently, no hedge funds are holding shares in HOOK
---
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
---
HOOK Stock 12 Month Forecast
Average Price Target
$2.00
▲(143.90% Upside)
Technical Analysis
Best Analysts Covering HOOK
1 Year
1 Year Success Rate
1/22 ratings generated profit
1 Year Average Return
-59.71%
reiterated a buy rating 8 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 4.55% of your transactions generating a profit, with an average return of -59.71% per trade.
---